Welcome, Guest
Username: Password: Remember me
Cytori´s Technology- Celution, IP etc etc
  • Page:
  • 1

TOPIC: Australian patent for ADRCs in Cardiac

Australian patent for ADRCs in Cardiac 10 Oct 2013 07:38 #955

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3332
  • Thank you received: 1114
Now this is somewhat better explained-

Cytori Therapeutics has received an Australian patent covering methods of treating cardiovascular disease using adipose-derived regenerative cells (ADRCs). The patent covers the therapeutic use of ADRCs for improving cardiac function and mechanics by preventing the deleterious histopathological and structural changes that occur in the heart following a heart attack (cardiac remodeling).

"This patent expands our growing body of global patents surrounding therapeutic uses for our Celution® cell output," said Christopher Calhoun, CEO of Cytori. "As previously reported, we are encouraged by the positive clinical results in our cardiovascular trials to date and cardiovascular disease remains a core focus of the Company."

The patent is not limited to any particular way of obtaining ADRCs, covering both manual and automated methods of obtaining the cells. This includes the use of a sterile, closed system such as Cytori's proprietary Celution® System. The claims also cover multiple cell populations and cell delivery methods, including intravenous delivery.

Cytori received notice from the Australian Therapeutic Goods Administration (TGA) that the Celution® System was approved for commercial use through inclusion on the Australian Registry of Therapeutic Goods for autologous re-implantation and re-infusion of a patient's own ADRCs in August 2013. This approval enables physicians to treat critical unmet medical needs with point-of-care cell therapies and to conduct important clinical research in promising therapeutic areas.

The patent complements Cytori's existing patents in Australia covering the Celution® System and builds upon the Company's global patent strategy encompassing therapeutic indication-specific, methods and device patents. Cytori now has 64 issued patents and more than 75 active patent applications worldwide.


This patent basically confirms the main aspects of fat cells including the Caplan theories or pericytes. That is- very potent in the ACUTE INJURY case and can even be delivered INTRAVENOUSLY since they find its way to the site of injury (homing)

In case not clear- this is a patent for ADRCs and is not directly related to Celution, but ALL methods to extract cells from fat to treat cardiac disorders with.
The following user(s) said Thank You: keysman

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:
  • Page:
  • 1
Time to create page: 0.101 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites